[1].中国甲状腺功能亢进症和其他原因 所致甲状腺毒症诊治指南[J].国际内分泌代谢杂志,2022,42(05):401-450.[doi:10.3760/cma.j.cn311282-20220624-00404]
点击复制

中国甲状腺功能亢进症和其他原因 所致甲状腺毒症诊治指南()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年05期
页码:
401-450
栏目:
指南与共识
出版日期:
2022-09-20

文章信息/Info

Title:
Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
作者:
中华医学会内分泌学分会 中国医师协会内分泌代谢科医师分会 中华医学会核医学分会 中华医学会外科学分会甲状腺及代谢外科学组 中国医师协会外科医师分会甲状腺外科医师委员会
Author(s):
Chinese Society of Endocrinology; Chinese Endocrinologist Association; Chinese Society of Nuclear Medicine; Thyroid and Metabolism Surgery Group, Chinese Society of Surgery; Committee of Thyroid Surgeons, Chinese Medical Association
关键词:
甲状腺功能亢进症;  甲状腺毒症;  指南;  诊治
Keywords:
Hyperthyroidism;  Thyrotoxicosis;  Guideline;  Diagnosis and management
DOI:
10.3760/cma.j.cn311282-20220624-00404
摘要:
甲状腺功能亢进症(甲亢)是内分泌系统的常见病,为了规范中国甲亢临床诊治,5个学会联合制定了本指南。指南结合该领域的科学证据及临床医生的经验,制定了107条推荐意见,内容涵盖了甲状腺毒症病因的鉴别、Graves病诊断和治疗方案的选择、对特殊人群的甲亢例如青少年甲亢、妊娠期甲亢、老年甲亢的个性化管理、甲亢特殊类型如Graves眼病、亚临床甲亢、甲状腺危象、药源性甲亢等临床诊治,指南适用于从事临床工作的内科、外科、核医学科、全科医学等科室的医生。 本指南与《中华内分泌代谢杂志》同步发表
Abstract:
Hyperthyroidism is a common endocrine disorder. To standardize the clinical diagnosis and treatment of hyperthyroidism in China, five societies jointly published this guideline. Based on scientific evidence and expert expertise in this area, the guideline has formulated 107 recommendations, covering the identification of the etiology of thyrotoxicosis, diagnosis and treatment options of Graves' disease, individualized management of hyperthyroidism in special populations such as adolescent hyperthyroidism, pregnancy hyperthyroidism and elderly hyperthyroidism, and the clinical diagnosis and treatment of special types of hyperthyroidism such as Graves' ophthalmopathy, subclinical hyperthyroidism, thyroid storm and drug-induced hyperthyroidism. The guideline is suitable for doctors engaged in clinical work in internal medicine, surgery, nuclear medicine, general practice and other departments. This guideline is published with 《Chinese Journal of Endocrinology and Metabolism》 simutaneously.

参考文献/References:

[1] Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis[J]. Thyroid, 2016,26(10):1343-1421. DOI: 10.1089/thy.2016.0229.
[2] Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study[J]. Eur Heart J, 2012,33(12):1500-1510. DOI: 10.1093/eurheartj/ehr488.
[3] Baumgartner C, da Costa BR, Collet TH, et al. Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation[J]. Circulation, 2017,136(22):2100-2116. DOI: 10.1161/CIRCULATIONAHA.117.028753.
[4] De Leo S, Lee SY, Braverman LE. Hyperthyroidism[J].Lancet(London),2016,388:906-918.DOI:10.1016/S0140-6736(16)00278-6.
[5] Biondi B, Cooper DS. Subclinical Hyperthyroidism[J]. N Engl J Med, 2018,378(25):2411-2419. DOI: 10.1056/NEJMcp1709318.
[6] 《妊娠和产后甲状腺疾病诊治指南》(第2版)编撰委员会, 中华医学会内分泌学分会, 中华医学会围产医学分会. 妊娠和产后甲状腺疾病诊治指南(第2版)[J]. 中华内分泌代谢杂志, 2019,35(8):636-665. DOI: 10.3760/cma.j.issn.1000-6699.2019.08.003.
[7] 《中国老年人甲状腺疾病诊疗专家共识》编委会. 中国老年人甲状腺疾病诊疗专家共识(2021). 中华内分泌代谢杂志, 2021,37(5):399-417. DOI: 10.3760/cma.j.cn311282-20210502-00273.
[8] Li Y, Teng D, Ba J, et al. Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: Epidemiological Evidence from 31 Provinces of Mainland China[J]. Thyroid, 2020,30(4):568-579. DOI: 10.1089/thy.2019.0067.
[9] Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden(Gothenburg)2003-2005[J]. Clin Endocrinol(Oxf), 2013,78(5):768-776. DOI: 10.1111/cen.12060.
[10] Gokowski F, Buziak-Bereza M, Trofimiuk M, et al. Increased prevalence of hyperthyroidism as an early and transient side-effect of implementing iodine prophylaxis[J]. Public Health Nutr, 2007,10(8):799-802. DOI: 10.1017/S1368980007585939.
[11] Amouzegar A, Gharibzadeh S, Kazemian E, et al. The Prevalence, Incidence and Natural Course of Positive Antithyroperoxidase Antibodies in a Population-Based Study: Tehran Thyroid Study[J]. PLoS One, 2017,12(1):e0169283. DOI: 10.1371/journal.pone.0169283.
[12] Teng W, Shan Z, Teng X, et al. Effect of iodine intake on thyroid diseases in China[J]. N Engl J Med, 2006,354(26):2783-2793. DOI: 10.1056/NEJMoa054022.
[13] Sharif K, Watad A, Coplan L, et al. The role of stress in the mosaic of autoimmunity: An overlooked association[J]. Autoimmun Rev, 2018,17(10):967-983. DOI: 10.1016/j.autrev.2018.04.005.
[14] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南—甲状腺功能亢进症[J]. 中华内科杂志, 2007,46(10):876-882. DOI: 10.3760/j.issn:0578-1426.2007.10.035.
[15] Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism[J]. Eur Thyroid J, 2018,7(4):167-186. DOI: 10.1159/000490384.
[16] Halsall DJ, Oddy S. Clinical and laboratory aspects of 3,3',5'-triiodothyronine(reverse T3)[J]. Ann Clin Biochem, 2021,58(1):29-37. DOI: 10.1177/0004563220969150.
[17] 滕卫平, 单忠艳. 甲状腺学[M]. 沈阳: 辽宁科学技术出版社, 2021.
[18] Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease[J]. Thyroid, 2003,13(1):3-126. DOI: 10.1089/105072503321086962.
[19] 马瑞婷, 黄慧, 严悦溶, 等. 正常成人甲状腺激素水平影响因素探讨[J]. 四川大学学报(医学版), 2015,46(4):611-614.
[20] 中华医学会检验分会, 卫生部临床检验中心, 中华检验医学杂志编辑委员会. 甲状腺疾病诊断治疗中实验室检测项目的应用建议[J]. 中华检验医学杂志, 2012,35(6):484-492. DOI: 10.3760/cma.j.issn.1009-9158.2012.06.002.
[21] Zouwail SA, O'Toole AM, Clark PM, et al. Influence of thyroid hormone autoantibodies on 7 thyroid hormone assays[J]. Clin Chem, 2008,54(5):927-928. DOI: 10.1373/clinchem.2007.099770.
[22] Favresse J, Burlacu MC, Maiter D, et al. Interferences With Thyroid Function Immunoassays: Clinical Implications and Detection Algorithm[J]. Endocr Rev, 2018,39(5):830-850. DOI: 10.1210/er.2018-00119.
[23] Norden AG, Jackson RA, Norden LE, et al. Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor[J]. Clin Chem, 1997,43(6 Pt 1):957-962.
[24] Kummer S, Hermsen D, Distelmaier F. Biotin Treatment Mimicking Graves' Disease[J]. N Engl J Med, 2016,375(7):704-706. DOI: 10.1056/NEJMc1602096.
[25] Soh SB, Aw TC. Laboratory Testing in Thyroid Conditions - Pitfalls and Clinical Utility[J]. Ann Lab Med, 2019,39(1):3-14. DOI: 10.3343/alm.2019.39.1.3.
[26] Kratzsch J, Baumann NA, Ceriotti F, et al. Global FT4 immunoassay standardization: an expert opinion review[J]. Clin Chem Lab Med, 2021,59(6):1013-1023. DOI: 10.1515/cclm-2020-1696.
[27] Yu S, Zhou W, Cheng X, et al. Comparison of Six Automated Immunoassays With Isotope-Diluted Liquid Chromatography-Tandem Mass Spectrometry for Total Thyroxine Measurement[J]. Ann Lab Med, 2019,39(4):381-387. DOI: 10.3343/alm.2019.39.4.381.
[28] de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients[J]. Arch Intern Med, 1989,149(3):526-532. DOI: 10.1001/archinte.149.3.526.
[29] National Guideline Centre. National Institute for Health and Care Excellence[M]. Thyroid disease: assessment and management. London: National Institute for Health and Care Excellence, 2019.
[30] Esfandiari NH, Papaleontiou M. Biochemical Testing in Thyroid Disorders[J]. Endocrinol Metab Clin North Am, 2017,46(3):631-648. DOI: 10.1016/j.ecl.2017.04.002.
[31] Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism[J]. Eur Thyroid J, 2015,4(3):149-163. DOI: 10.1159/000438750.
[32] Iyer S, Bahn R. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor[J]. Best Pract Res Clin Endocrinol Metab, 2012,26(3):281-289. DOI: 10.1016/j.beem.2011.10.003.
[33] Melmed S, Polonsky K S, Larsen P R,et al. Williams Textbook of Endocrinology[M]. Philadelphia: Elsevier, 2015.
[34] Kim JJ, Jeong SH, Kim B, et al. Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay[J]. Scand J Clin Lab Invest, 2019,79(6):443-448. DOI: 10.1080/00365513.2019.1658216.
[35] Allelein S, Ehlers M, Goretzki S, et al. Clinical Evaluation of the First Automated Assay for the Detection of Stimulating TSH Receptor Autoantibodies[J]. Horm Metab Res, 2016,48(12):795-801. DOI: 10.1055/s-0042-121012.
[36] Bednarczuk T, Brix TH, Schima W, et al. 2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction[J]. Eur Thyroid J, 2021,10(4):269-284. DOI: 10.1159/000517175.
[37] 陈立立, 俞一飞, 曾芳芳, 等. 第3代促甲状腺素受体抗体测定法(Elecsys)对甲状腺毒血症的鉴别诊断价值[J]. 中国临床医学, 2021,28(1):80-84. DOI: 10.12025/j.issn.1008-6358.2021.20201871.
[38] Vos XG, Smit N, Endert E, et al. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study[J]. Clin Endocrinol(Oxf), 2008,69(2):311-317. DOI: 10.1111/j.1365-2265.2008.03192.x.
[39] Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease[J]. J Clin Endocrinol Metab, 2006,91(9):3464-3470. DOI: 10.1210/jc.2005-2813.
[40] Zimmer KP, Schmid KW, Böcker W, et al. Transcytosis of IgG from the basolateral to the apical membrane of human thyrocytes in autoimmune thyroid disease[J]. Curr Top Pathol, 1997,91:117-128. DOI: 10.1007/978-3-642-60531-4_9.
[41] La'ulu SL, Slev PR, Roberts WL. Performance characteristics of 5 automated thyroglobulin autoantibody and thyroid peroxidase autoantibody assays[J]. Clin Chim Acta, 2007,376(1-2):88-95. DOI: 10.1016/j.cca.2006.07.018.
[42] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医疗保健国际交流促进会临床实用技术分会. 甲状腺功能亢进症外科治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020,40(11):1229-1233. DOI: 10.19538/j.cjps.issn1005-2208.2020.11.01.
[43] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 甲状腺功能亢进症基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2019,18(12):1118-1128. DOI: 10.3760/cma.j.issn.1671-7368.2019.12.002.
[44] Poppe K, Bisschop P, Fugazzola L, et al. 2021 European Thyroid Association Guideline on Thyroid Disorders prior to and during Assisted Reproduction[J]. Eur Thyroid J, 2021,9(6):281-295. DOI: 10.1159/000512790.
[45] Schenke SA, Görges R, Seifert P, et al. Update on diagnosis and treatment of hyperthyroidism: ultrasonography and functional imaging[J]. Q J Nucl Med Mol Imaging, 2021,65(2):102-112. DOI: 10.23736/S1824-4785.21.03333-1.
[46] Erdo(ˇoverg)an MF, Anil C, Cesur M, et al. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism[J]. Thyroid, 2007,17(3):223-228. DOI: 10.1089/thy.2006.0104.
[47] Bogazzi F, Vitti P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease?[J]. Nat Clin Pract Endocrinol Metab, 2008,4(2):70-71. DOI: 10.1038/ncpendmet0692.
[48] Pedersen IB, Knudsen N, Perrild H, et al. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays[J]. Clin Endocrinol(Oxf), 2001,55(3):381-390. DOI: 10.1046/j.1365-2265.2001.01347.x.
[49] Kim TK, Lee EJ. The value of the mean peak systolic velocity of the superior thyroidal artery in the differential diagnosis of thyrotoxicosis[J]. Ultrasonography, 2015,34(4):292-296. DOI: 10.14366/usg.14059.
[50] Kurita S, Sakurai M, Kita Y, et al. Measurement of thyroid blood flow area is useful for diagnosing the cause of thyrotoxicosis[J]. Thyroid, 2005,15(11):1249-1252. DOI: 10.1089/thy.2005.15.1249.
[51] Ota H, Amino N, Morita S, et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease[J]. Clin Endocrinol(Oxf), 2007,67(1):41-45. DOI: 10.1111/j.1365-2265.2007.02832.x.
[52] Uchida T, Takeno K, Goto M, et al. Superior thyroid artery mean peak systolic velocity for the diagnosis of thyrotoxicosis in Japanese patients[J]. Endocr J, 2010,57(5):439-443. DOI: 10.1507/endocrj.k09e-263.
[53] Peng X, Wu S, Bie C, et al. Mean peak systolic velocity of superior thyroid artery for the differential diagnosis of thyrotoxicosis: a diagnostic meta-analysis[J]. BMC Endocr Disord, 2019,19(1):56. DOI: 10.1186/s12902-019-0388-x.
[54] 薛萌, 石秋玲, 谭坤能, 等. 彩色多普勒超声、甲状腺功能及甲状腺自身抗体检查在鉴别妊娠甲状腺功能亢进和Graves病中的价值[J]. 中华内科杂志, 2016,55(6):470-473. DOI: 10.3760/cma.j.issn.0578-1426.2016.06.014.
[55] Chung J, Lee YJ, Choi YJ, et al. Clinical applications of Doppler ultrasonography for thyroid disease: consensus statement by the Korean Society of Thyroid Radiology[J]. Ultrasonography, 2020,39(4):315-330. DOI: 10.14366/usg.20072.
[56] Alzahrani AS, Ceresini G, Aldasouqi SA. Role of ultrasonography in the differential diagnosis of thyrotoxicosis: a noninvasive, cost-effective, and widely available but underutilized diagnostic tool[J]. Endocr Pract, 2012,18(4):567-578. DOI: 10.4158/EP11170.RA.
[57] 姜晓华, 方微园, 叶蕾, 等. 甲状腺激素抵抗综合征的临诊应对[J]. 中华内分泌代谢杂志, 2013,29(2):165-169. DOI: 10.3760/cma.j.issn.1000-6699.2013.02.018.
[58] Campi I, Covelli D, Moran C, et al. The Differential Diagnosis of Discrepant Thyroid Function Tests: Insistent Pitfalls and Updated Flow-Chart Based on a Long-Standing Experience[J]. Front Endocrinol(Lausanne), 2020,11:432. DOI: 10.3389/fendo.2020.00432.
[59] Han R, Shen L, Zhang J, et al. Diagnosing Thyrotropin-Secreting Pituitary Adenomas by Short-Term Somatostatin Analogue Test[J]. Thyroid, 2020,30(9):1236-1244. DOI: 10.1089/thy.2019.0470.
[60] Akamizu T, Satoh T, Isozaki O, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys[J]. Thyroid, 2012,22(7):661-679. DOI: 10.1089/thy.2011.0334.
[61] Angell TE, Lechner MG, Nguyen CT, et al. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study[J]. J Clin Endocrinol Metab, 2015,100(2):451-459. DOI: 10.1210/jc.2014-2850.
[62] Klein I, Danzi S. Thyroid Disease and the Heart[J]. Curr Probl Cardiol, 2016,41(2):65-92. DOI: 10.1016/j.cpcardiol.2015.04.002.
[63] Swee du S, Chng CL, Lim A. Clinical characteristics and outcome of thyroid storm: a case series and review of neuropsychiatric derangements in thyrotoxicosis[J]. Endocr Pract, 2015,21(2):182-189. DOI: 10.4158/EP14023.OR.
[64] Nayak B, Burman K. Thyrotoxicosis and thyroid storm[J]. Endocrinol Metab Clin North Am, 2006,35(4):663-686, vii. DOI: 10.1016/j.ecl.2006.09.008.
[65] Pereira JV, Lim T. Hyperthyroidism in gestational trophoblastic disease - a literature review[J]. Thyroid Res, 2021,14(1):1. DOI: 10.1186/s13044-021-00092-3.
[66] Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm[J]. Endocrinol Metab Clin North Am, 1993,22(2):263-277.
[67] Abuid J, Larsen PR. Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents[J]. J Clin Invest, 1974,54(1):201-208. DOI: 10.1172/JCI107744.
[68] Cooper DS, Saxe VC, Meskell M, et al. Acute effects of propylthiouracil(PTU)on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay[J]. J Clin Endocrinol Metab, 1982,54(1):101-107. DOI: 10.1210/jcem-54-1-101.
[69] Tyer NM, Kim TY, Martinez DS. Review of oral cholecystographic agents for the management of hyperthyroidism[J]. Endocr Pract, 2014,20(10):1084-1092. DOI: 10.4158/EP14024.RA.
[70] Chopra IJ, Williams DE, Orgiazzi J, et al. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine(reverse T3)and 3,3'5-triiodothyronine(T3)[J]. J Clin Endocrinol Metab, 1975,41(5):911-920. DOI: 10.1210/jcem-41-5-911.
[71] Cooper DS, Daniels GH, Ladenson PW, et al. Hyperthyroxinemia in patients treated with high-dose propranolol[J]. Am J Med, 1982,73(6):867-871. DOI: 10.1016/0002-9343(82)90778-1.
[72] Muller C, Perrin P, Faller B, et al. Role of plasma exchange in the thyroid storm[J]. Ther Apher Dial, 2011,15(6):522-531. DOI: 10.1111/j.1744-9987.2011.01003.x.
[73] Scholz GH, Hagemann E, Arkenau C, et al. Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure?[J]. Thyroid, 2003,13(10):933-940. DOI: 10.1089/105072503322511337.
[74] Turner P. Beta-adrenergic receptor blocking drugs in hyperthyroidism[J]. Drugs, 1974,7(1):48-54. DOI: 10.2165/00003495-197407010-00004.
[75] Clozel JP, Danchin N, Genton P, et al. Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism[J]. Clin Pharmacol Ther, 1984,36(1):64-69. DOI: 10.1038/clpt.1984.140.
[76] Roti E, Montermini M, Roti S, et al. The effect of diltiazem, a calcium channel-blocking drug, on cardiac rate and rhythm in hyperthyroid patients[J]. Arch Intern Med, 1988,148(9):1919-1921.
[77] Kele �瘙 塂 timur F, Aksu A. The effect of diltiazem on the manifestations of hyperthyroidism and thyroid function tests[J]. Exp Clin Endocrinol Diabetes, 1996,104(1):38-42. DOI: 10.1055/s-0029-1211420.
[78] Nordin H, Galløe AM, Ladefoged SD, et al. The effects of propranolol and verapamil on hyperthyroid heart symptoms and function, assessed by systolic time intervals[J]. Acta Endocrinol(Copenh), 1993,128(4):297-300. DOI: 10.1530/acta.0.1280297.
[79] Cooper DS. Antithyroid drugs[J]. N Engl J Med, 2005,352(9):905-917. DOI: 10.1056/NEJMra042972.
[80] Abraham P, Avenell A, McGeoch SC, et al. Antithyroid drug regimen for treating Graves' hyperthyroidism[J]. Cochrane Database Syst Rev, 2010,(1):CD003420. DOI: 10.1002/14651858.CD003420.pub4.
[81] Liu X, Qiang W, Liu X, et al. A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice[J]. Eur J Endocrinol, 2015,172(3):321-326. DOI: 10.1530/EJE-14-0704.
[82] Carella C, Mazziotti G, Sorvillo F, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period[J]. Thyroid, 2006,16(3):295-302. DOI: 10.1089/thy.2006.16.295.
[83] Li J, Bai L, Wei F, et al. Effect of Addition of Thyroxine in the Treatment of Graves' Disease: A Systematic Review[J]. Front Endocrinol(Lausanne), 2020,11:560157. DOI: 10.3389/fendo.2020.560157.
[84] Ikeda S, Schweiss JF. Excessive blood loss during operation in the patient treated with propylthiouracil[J]. Can Anaesth Soc J, 1982,29(5):477-480. DOI: 10.1007/BF03009412.
[85] Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration[J]. Clin Endocrinol(Oxf), 2012,77(2):310-315. DOI: 10.1111/j.1365-2265.2012.04365.x.
[86] Aggarwal N, Tee SA, Saqib W, et al. Treatment of hyperthyroidism with antithyroid drugs corrects mild neutropenia in Graves' disease[J]. Clin Endocrinol(Oxf), 2016,85(6):949-953. DOI: 10.1111/cen.13133.
[87] Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration[J]. Clin Endocrinol(Oxf), 2012,77(2):310-315. DOI: 10.1111/j.1365-2265.2012.04365.x.
[88] Scappaticcio L, Longo M, Maiorino MI, et al. Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis[J]. Thyroid, 2021,31(6):884-894. DOI: 10.1089/thy.2020.0715.
[89] He Y, Li J, Zheng J, et al. Emphasis on the early diagnosis of antithyroid drug-induced agranulocytosis: retrospective analysis over 16 years at one Chinese center[J]. J Endocrinol Invest, 2017,40(7):733-740. DOI: 10.1007/s40618-017-0626-x.
[90] Andersen SL, Olsen J, Laurberg P. Antithyroid Drug Side Effects in the Population and in Pregnancy[J]. J Clin Endocrinol Metab, 2016,101(4):1606-1614. DOI: 10.1210/jc.2015-4274.
[91] Watanabe N, Narimatsu H, Noh JY, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease[J]. J Clin Endocrinol Metab, 2012,97(1):E49-53. DOI: 10.1210/jc.2011-2221.
[92] Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan[J]. J Clin Endocrinol Metab, 2013,98(12):4776-4783. DOI: 10.1210/jc.2013-2569.
[93] Azizi F, Malboosbaf R. Safety of long-term antithyroid drug treatment? A systematic review[J]. J Endocrinol Invest, 2019,42(11):1273-1283. DOI: 10.1007/s40618-019-01054-1.
[94] Chen PL, Shih SR, Wang PW, et al. Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study[J]. Nat Commun, 2015,6:7633. DOI: 10.1038/ncomms8633.
[95] Chen WT, Chi CC. Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies[J]. Br J Clin Pharmacol, 2019,85(9):1878-1887. DOI: 10.1111/bcp.13989.
[96] He Y, Zheng J, Zhang Q, et al. Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China[J]. Sci Rep, 2017,7(1):11950. DOI: 10.1038/s41598-017-12350-2.
[97] Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily[J]. Thyroid, 2009,19(6):559-563. DOI: 10.1089/thy.2008.0364.
[98] Andrès E, Kurtz JE, Perrin AE, et al. Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis[J]. QJM, 2001,94(8):423-428. DOI: 10.1093/qjmed/94.8.423.
[99] Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs[J]. Ann Intern Med, 2007,146(9):657-665. DOI: 10.7326/0003-4819-146-9-200705010-00009.
[100] Meyer-Gessner M, Benker G, Lederbogen S, et al. Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature[J]. J Endocrinol Invest, 1994,17(1):29-36. DOI: 10.1007/BF03344959.
[101] Tajiri J, Noguchi S, Murakami T, et al. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring[J]. Arch Intern Med, 1990,150(3):621-624. DOI: 10.1001/archinte.150.3.621.
[102] Ahmed K, Rao S, Simha V. Antineutrophil cytoplasmic antibody-positive vasculitis in a patient with graves disease: cross-reaction between propylthiouracil and methimazole[J]. Endocr Pract, 2010,16(3):449-451. DOI: 10.4158/EP09304.CR.
[103] 柴晓峰, 连小兰. 粒细胞集落刺激因子治疗抗甲状腺药物致粒细胞缺乏症36例疗效分析[J]. 中国实用内科杂志, 2017,37(10):917-919. DOI: 10.19538/j.nk2017100113.
[104] Burch HB, Cooper DS. Management of Graves Disease: A Review[J]. JAMA, 2015,314(23):2544-2554. DOI: 10.1001/jama.2015.16535.
[105] Woeber KA. Methimazole-induced hepatotoxicity[J]. Endocr Pract, 2002,8(3):222-224. DOI: 10.4158/EP.8.3.222.
[106] Kim HJ, Kim BH, Han YS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study[J]. Am J Gastroenterol, 2001,96(1):165-169. DOI: 10.1111/j.1572-0241.2001.03469.x.
[107] Wang MT, Lee WJ, Huang TY, et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study[J]. Br J Clin Pharmacol, 2014,78(3):619-629. DOI: 10.1111/bcp.12336.
[108] Yang J, Li LF, Xu Q, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China[J]. Thyroid, 2015,25(3):278-283. DOI: 10.1089/thy.2014.0350.
[109] Li X, Yang J, Jin S, et al. Mechanistic examination of methimazole-induced hepatotoxicity in patients with Grave's disease: a metabolomic approach[J]. Arch Toxicol, 2020,94(1):231-244. DOI: 10.1007/s00204-019-02618-z.
[110] Suzuki N, Noh JY, Hiruma M, et al. Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan[J]. Thyroid, 2019,29(10):1390-1398. DOI: 10.1089/thy.2019.0045.
[111] 段然, 李静. 甲状腺功能亢进症合并肝损害的鉴别诊断和处理[J]. 中国实用内科杂志, 2018,38(10):971-973. DOI: 10.19538/j.nk2018100122.
[112] Noh JY, Yasuda S, Sato S, et al. Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs[J]. J Clin Endocrinol Metab, 2009,94(8):2806-2811. DOI: 10.1210/jc.2008-2700.
[113] Aloush V, Litinsky I, Caspi D, et al. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management[J]. Semin Arthritis Rheum, 2006,36(1):4-9. DOI: 10.1016/j.semarthrit.2006.03.003.
[114] Balavoine AS, Glinoer D, Dubucquoi S, et al. Antineutrophil Cytoplasmic Antibody-Positive Small-Vessel Vasculitis Associated with Antithyroid Drug Therapy: How Significant Is the Clinical Problem?[J]. Thyroid, 2015,25(12):1273-1281. DOI: 10.1089/thy.2014.0603.
[115] Chen M, Gao Y, Guo XH, et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis[J]. Nat Rev Nephrol, 2012,8(8):476-483. DOI: 10.1038/nrneph.2012.108.
[116] Gao Y, Zhao MH, Guo XH, et al. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies(ANCA)in Chinese patients with hyperthyroidism[J]. Endocr Res, 2004,30(2):205-213. DOI: 10.1081/erc-120037729.
[117] Slot MC, Links TP, Stegeman CA, et al. Occurrence of antineutrophil cytoplasmic antibodies and associated vasculitis in patients with hyperthyroidism treated with antithyroid drugs: A long-term followup study[J]. Arthritis Rheum, 2005,53(1):108-113. DOI: 10.1002/art.20927.
[118] Gunton JE, Stiel J, Clifton-Bligh P, et al. Prevalence of positive anti-neutrophil cytoplasmic antibody(ANCA)in patients receiving anti-thyroid medication[J]. Eur J Endocrinol, 2000,142(6):587. DOI: 10.1530/eje.0.1420587.
[119] Gao Y, Chen M, Ye H, et al. The target antigens of antineutrophil cytoplasmic antibodies(ANCA)induced by propylthiouracil[J]. Int Immunopharmacol, 2007,7(1):55-60. DOI: 10.1016/j.intimp.2006.07.033.
[120] Yang J, Yao LP, Dong MJ, et al. Clinical Characteristics and Outcomes of Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Patients with Graves' Disease: A Median 38-Month Retrospective Cohort Study from a Single Institution in China[J]. Thyroid, 2017,27(12):1469-1474. DOI: 10.1089/thy.2017.0468.
[121] Gao Y, Chen M, Ye H, et al. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis[J]. Rheumatology(Oxford), 2008,47(10):1515-1520. DOI: 10.1093/rheumatology/ken321.
[122] Gao Y, Chen M, Ye H, et al. Follow-up of avidity and titre of anti-myeloperoxidase antibodies in sera from patients with propylthiouracil-induced vasculitis[J]. Clin Endocrinol(Oxf), 2007,66(4):543-547. DOI: 10.1111/j.1365-2265.2007.02770.x.
[123] Yazisiz V, Ongüt G, Terzio(ˇoverg)lu E, et al. Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment[J]. Int J Clin Pract, 2010,64(1):19-24. DOI: 10.1111/j.1742-1241.2007.01485.x.
[124] 中华医学会核医学分会. 131I治疗格雷夫斯甲亢指南(2021版)[J]. 中华核医学与分子影像杂志, 2021,41(4):242-253. DOI: 10.3760/cma.j.cn321828-20201109-00405.
[125] 柴锦燕, 谭建, 张桂芝,等. 复方碘溶液对格雷夫斯病患者摄131I功能及131I疗效的影响[J]. 中华核医学与分子影像杂志, 2019,2019(1):24-27. DOI: 10.3760/cma.j.issn.2095-2848.2019.01.007.
[126] Tagami T, Yambe Y, Tanaka T, et al. Short-term effects of β-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves' disease[J]. Intern Med, 2012,51(17):2285-2290. DOI: 10.2169/internalmedicine.51.7302.
[127] Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome[J]. Endocr Rev, 2012,33(6):920-980. DOI: 10.1210/er.2012-1030.
[128] 杨吉生, 王强, 胡明造, 等. Graves病再次131I治疗的剂量计算和病例选择[J]. 中华核医学杂志, 2001,21(1):16. DOI: 10.3760/cma.j.issn.2095-2848.2001.01.022.
[129] Graham GD, Burman KD. Radioiodine treatment of Graves' disease. An assessment of its potential risks[J]. Ann Intern Med, 1986,105(6):900-905. DOI: 10.7326/0003-4819-105-6-900.
[130] 刘丽娜, 刘斌, 黄蕤, 等. 核医学诊疗的辐射防护与安全[J]. 中国医学影像技术, 2017,33(12):1888-1892. DOI: 10.13929/j.1003-3289.201707009.
[131] Bartalena L, Chiovato L, Vitti P. Management of hyperthyroidism due to Graves' disease: frequently asked questions and answers(if any)[J]. J Endocrinol Invest, 2016,39(10):1105-1114. DOI: 10.1007/s40618-016-0505-x.
[132] Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group[J]. JAMA, 1998,280(4):347-355. DOI: 10.1001/jama.280.4.347.
[133] Shim SR, Kitahara CM, Cha ES, et al. Cancer Risk After Radioactive Iodine Treatment for Hyperthyroidism: A Systematic Review and Meta-analysis[J]. JAMA Netw Open, 2021,4(9):e2125072. DOI: 10.1001/jamanetworkopen.2021.25072.
[134] American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association[J]. Thyroid, 2011,21(4):335-346. DOI: 10.1089/thy.2010.0403.
[135] Liu B, Tian R, Peng W, et al. Radiation Safety Precautions in(131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements[J]. J Clin Endocrinol Metab, 2015,100(8):2934-2941. DOI: 10.1210/jc.2015-1682.
[136] 中华人民共和国卫生和计划生育委员会. 临床核医学患者防护要求[M]. 中华人民共和国卫生行业标准(WS 533-2017), 2017-11-01.
[137] Hamilton L, Lim AE, Clark LJ. Total thyroidectomy for Graves' disease-what do our patients think? A qualitative cohort study to evaluate the surgical management of Graves' disease[J]. Surgeon, 2020,18(4):193-196. DOI: 10.1016/j.surge.2019.09.005.
[138] Minuto MN, Reina S, Monti E, et al. Morbidity following thyroid surgery: acceptable rates and how to manage complicated patients[J]. J Endocrinol Invest, 2019,42(11):1291-1297. DOI: 10.1007/s40618-019-01064-z.
[139] Akamizu T. Thyroid Storm: A Japanese Perspective[J]. Thyroid, 2018,28(1):32-40. DOI: 10.1089/thy.2017.0243.
[140] Erbil Y, Ozluk Y, Giri �瘙 塂 M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease[J]. J Clin Endocrinol Metab, 2007,92(6):2182-2189. DOI: 10.1210/jc.2007-0229.
[141] 付言涛, 孙辉. 甲状腺功能亢进病人围手术期碘准备临床进展[J]. 中国实用外科杂志, 2018,38(6):630-634. DOI: 10.19538/j.cjps.issn1005-2208.2018.06.11.
[142] Corvilain B, Hamy A, Brunaud L, et al. Treatment of adult Graves' disease[J]. Ann Endocrinol(Paris), 2018,79(6):618-635. DOI: 10.1016/j.ando.2018.08.003.
[143] Yabuta T, Ito Y, Hirokawa M, et al. Preoperative administration of excess iodide increases thyroid volume of patients with Graves' disease[J]. Endocr J, 2009,56(3):371-375. DOI: 10.1507/endocrj.k08e-240.
[144] 朱精强, 李志辉, 魏涛, 等. 甲状腺功能衰竭法在甲状腺功能亢进手术前准备的前瞻性研究[J]. 四川大学学报(医学版), 2007,38(5):866-870. DOI: 10.3969/j.issn.1672-173X.2007.05.031.
[145] 朱精强, 刘枫. 甲状腺功能亢进的外科治疗之我见[J]. 医学与哲学, 2013,34(18):22-24,30.
[146] 梁青壮, 易辛, 李朋, 等. 甲状腺功能亢进患者围手术期不服碘剂的探讨[J]. 中华普通外科杂志, 2019,34(9):810-811. DOI: 10.3760/cma.j.issn.1007-631X.2019.09.019.
[147] Ali A, Debono M, Balasubramanian SP. Outcomes After Urgent Thyroidectomy Following Rapid Control of Thyrotoxicosis in Graves' Disease are Similar to Those After Elective Surgery in Well-Controlled Disease[J]. World J Surg, 2019,43(12):3051-3058. DOI: 10.1007/s00268-019-05125-5.
[148] 卢秀波, 王庆兆, 张静, 等. 地塞米松在原发性甲状腺功能亢进症围手术期的应用[J]. 郑州大学学报(医学版), 2002,37(4):417-419. DOI: 10.3969/j.issn.1671-6825.2002.04.007.
[149] Edafe O, Antakia R, Laskar N, et al. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia[J]. Br J Surg, 2014,101(4):307-320. DOI: 10.1002/bjs.9384.
[150] Oltmann SC, Brekke AV, Schneider DF, et al. Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study[J]. Ann Surg Oncol, 2015,22(3):952-958. DOI: 10.1245/s10434-014-4077-8.
[151] Kim WW, Chung SH, Ban EJ, et al. Is Preoperative Vitamin D Deficiency a Risk Factor for Postoperative Symptomatic Hypocalcemia in Thyroid Cancer Patients Undergoing Total Thyroidectomy Plus Central Compartment Neck Dissection?[J]. Thyroid, 2015,25(8):911-918. DOI: 10.1089/thy.2014.0522.
[152] Genser L, Trésallet C, Godiris-Petit G, et al. Randomized controlled trial of alfacalcidol supplementation for the reduction of hypocalcemia after total thyroidectomy[J]. Am J Surg, 2014,207(1):39-45. DOI: 10.1016/j.amjsurg.2013.05.007.
[153] Testa A, Fant V, De Rosa A, et al. Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia[J]. Horm Metab Res, 2006,38(12):821-826. DOI: 10.1055/s-2006-956504.
[154] Antakia R, Edafe O, Uttley L, et al. Effectiveness of preventative and other surgical measures on hypocalcemia following bilateral thyroid surgery: a systematic review and meta-analysis[J]. Thyroid, 2015,25(1):95-106. DOI: 10.1089/thy.2014.0101.
[155] Bobanga ID, McHenry CR. Treatment of patients with Graves' disease and the appropriate extent of thyroidectomy[J]. Best Pract Res Clin Endocrinol Metab, 2019,33(4):101319. DOI: 10.1016/j.beem.2019.101319.
[156] Sugino K, Nagahama M, Kitagawa W, et al. Change of surgical strategy for Graves' disease from subtotal thyroidectomy to total thyroidectomy: a single institutional experience[J]. Endocr J, 2019,66(2):181-186. DOI: 10.1507/endocrj.EJ18-0324.
[157] Sung TY, Lee YM, Yoon JH, et al. Long-Term Effect of Surgery in Graves' Disease: 20 Years Experience in a Single Institution[J]. Int J Endocrinol, 2015,2015:542641. DOI: 10.1155/2015/542641.
[158] Sosa JA, Mehta PJ, Wang TS, et al. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost?[J]. J Am Coll Surg, 2008,206(6):1097-1105. DOI: 10.1016/j.jamcollsurg.2007.11.023.
[159] Ylli D, Klubo-Gwiezdzinska J, Wartofsky L. Thyroid emergencies[J]. Pol Arch Intern Med, 2019,129(7-8):526-53

相似文献/References:

[1]曹雯,郑仁东,陈国芳,等.甲状腺功能亢进症伴严重药物性胆汁郁积性肝炎1例并文献复习[J].国际内分泌代谢杂志,2014,(03):214.[doi:10.3760/cma.j.issn.1673-4157.2014.03.020]
　Cao Wen,Zheng Rendong,Chen Guofang,et al.One case of hyperthyroidism with severe drug-induced cholestasis hepatitis and literature review[J].International Journal of Endocrinology and Metabolism,2014,(05):214.[doi:10.3760/cma.j.issn.1673-4157.2014.03.020]
[2]陈堃,陈国芳,郑仁东,等.碳酸锂对甲状腺功能和形态的影响[J].国际内分泌代谢杂志,2014,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2014.04.009]
　Chen Kun,Chen Guofang,Zheng Rendong,et al.Effects of carbonate lithium therapy on morphology and function of thyroid gland[J].International Journal of Endocrinology and Metabolism,2014,(05):248.[doi:10.3760/cma.j.issn.1673-4157.2014.04.009]
[3]姚瑶,郑仁东,刘超.血浆置换治疗甲状腺功能亢进症的研究进展[J].国际内分泌代谢杂志,2020,40(05):320.[doi:10.3760/cma.j.cn121383-20191218-12047]
　Yao Yao,Zheng Rendong,Liu Chao.Update on plasmapheresis for hyperthyroidism[J].International Journal of Endocrinology and Metabolism,2020,40(05):320.[doi:10.3760/cma.j.cn121383-20191218-12047]
[4]龙丽 张秀英 纪立农.甲状腺相关眼病治疗新希望——IGF-Ⅰ受体拮抗剂[J].国际内分泌代谢杂志,2022,42(04):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
　Long Li,Zhang Xiuying,Ji Linong..New hope for the treatment of thyroid associated orbitopathy-IGF-Ⅰ receptor antagonist[J].International Journal of Endocrinology and Metabolism,2022,42(05):256.[doi:10.3760/cma.j.cn121383-20210420-04055]
[5]邢渝敏,单忠艳.碘营养与甲状腺功能亢进症:共识与争议[J].国际内分泌代谢杂志,2023,43(04):287.[doi:10.3760/cma.j.cn121383-20230508-05010]
　Xing Yumin,Shan Zhongyan.Iodine nutrition and hyperthyroidism: consensus and controversy[J].International Journal of Endocrinology and Metabolism,2023,43(05):287.[doi:10.3760/cma.j.cn121383-20230508-05010]

备注/Memo

备注/Memo:
通信作者:单忠艳(中国医科大学附属第一医院内分泌与代谢病科,沈阳 110001),Email:cmushanzhongyan@163.com
更新日期/Last Update: 2022-09-10